Literature DB >> 6183334

Neutralization of native human gamma interferon (HuIFN gamma) by antibodies to a synthetic peptide encoded by the 5' end of HuIFN gamma cDNA.

H M Johnson, M P Langford, B Lakhchaura, T S Chan, G J Stanton.   

Abstract

A synthetic peptide corresponding to the N-terminal amino acid sequence of human gamma-interferon (HuIFN gamma), based on the cDNA sequence, was used to produce antibodies in rabbits that were reactive with native HuIFN gamma. Antibodies from all immunized rabbits neutralized the antiviral activity of HuIFN gamma. Significant neutralization of other HuIFN and mouse IFN was not observed. The peptide had the sequence Cys-Tyr-Cys-Gln-Asp-Pro-Tyr-Val-Lys-Glu-Ala-Glu-Asn-Leu-Lys-Lys-Tyr-Phe-Asn-Ala ,and was coupled to keyhole limpet hemocyanin by disulfide linkage with the use of cystamine. The specificity of the antibodies produced to the peptide was compared to that of antibodies produced to native HuIFN gamma by neutralization of HuIFN gamma and by reactivity with peptide in the enzyme-linked immunosorbent assay (ELISA). The ratio of anti-peptide antibody neutralization of HuIFN gamma vs reactivity with peptide in the ELISA was at least 28-fold lower than for anti-HuIFN gamma antibody. Thus the antibodies to peptide and to HuIFN gamma were directed primarily against different determinants on native HuIFN gamma or the anti-HuIFN gamma antiserum probably contained antibodies to additional determinants. The anti-peptide antibodies should be useful for further characterization and purification of HuIFN gamma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6183334

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Natural and recombinant interferons inhibit epithelial cell invasion by Shigella spp.

Authors:  D W Niesel; C B Hess; Y J Cho; K D Klimpel; G R Klimpel
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

2.  Similarity between the corticotropin (ACTH) receptor and a peptide encoded by an RNA that is complementary to ACTH mRNA.

Authors:  K L Bost; E M Smith; J E Blalock
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

Review 3.  Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity.

Authors:  Elise Alspach; Danielle M Lussier; Robert D Schreiber
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-03-01       Impact factor: 10.005

4.  A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus.

Authors:  G Riemekasten; J Marell; G Trebeljahr; R Klein; G Hausdorf; T Häupl; J Schneider-Mergener; G R Burmester; F Hiepe
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

5.  Interleukin 2 enhances natural killer cell activity through induction of gamma interferon.

Authors:  D A Weigent; G J Stanton; H M Johnson
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

6.  Induction of human gamma interferon by structurally defined polypeptide fragments of group A streptococcal M protein.

Authors:  D A Weigent; E H Beachey; T Huff; J W Peterson; G J Stanton; S Baron
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

7.  Regulation of human peripheral blood monocyte DR antigen expression in vitro by lymphokines and recombinant interferons.

Authors:  M B Sztein; P S Steeg; H M Johnson; J J Oppenheim
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

8.  Streptococcus pneumoniae cocultured with fibroblasts enhances both interferon production and cytotoxic activity by lymphocytes.

Authors:  D A Weigent; S Baron; G J Stanton
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

9.  Potentiation of lymphocyte natural killing by mixtures of alpha or beta interferon with recombinant gamma interferon.

Authors:  D A Weigent; M P Langford; W R Fleischmann; G J Stanton
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.